rs398124603
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_183050.4(BCKDHB):c.970C>T(p.Arg324Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000026 in 1,613,042 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_183050.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BCKDHB | NM_183050.4 | c.970C>T | p.Arg324Ter | stop_gained | 9/10 | ENST00000320393.9 | NP_898871.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BCKDHB | ENST00000320393.9 | c.970C>T | p.Arg324Ter | stop_gained | 9/10 | 1 | NM_183050.4 | ENSP00000318351 | P1 | |
BCKDHB | ENST00000356489.9 | c.970C>T | p.Arg324Ter | stop_gained | 9/11 | 1 | ENSP00000348880 | P1 | ||
BCKDHB | ENST00000468520.1 | n.200C>T | non_coding_transcript_exon_variant | 3/3 | 5 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 152034Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000598 AC: 15AN: 250890Hom.: 0 AF XY: 0.0000590 AC XY: 8AN XY: 135574
GnomAD4 exome AF: 0.0000274 AC: 40AN: 1461008Hom.: 0 Cov.: 30 AF XY: 0.0000248 AC XY: 18AN XY: 726822
GnomAD4 genome AF: 0.0000132 AC: 2AN: 152034Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74262
ClinVar
Submissions by phenotype
Maple syrup urine disease Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | May 07, 2019 | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. This variant has been previously reported as disease-causing [PMID 9375800, 26232051, 25525159] - |
Likely pathogenic, criteria provided, single submitter | literature only | Counsyl | Sep 23, 2014 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 07, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 17, 2023 | This sequence change creates a premature translational stop signal (p.Arg324*) in the BCKDHB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BCKDHB are known to be pathogenic (PMID: 16786533, 22593002). This variant is present in population databases (rs398124603, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with maple syrup urine disease (PMID: 20307994, 22593002, 24772966, 26232051). This variant is also known as p.Arg274*. ClinVar contains an entry for this variant (Variation ID: 96621). For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Aug 27, 2016 | The BCKDHB c.970C>T (p.Arg324Ter) stop-gained variant is reported in five studies in a total of six individuals with maple syrup urine disease, including one who was homozygous for the variant and five, including a sibling pair, who were compound heterozygous (McConnell et al. 1997; Puckett et al. 2010; Bashyam et al. 2012; Narayanan et al. 2013; Couce et al. 2015). The p.Arg324Ter variant was absent from 100 controls and is reported at a frequency of 0.00044 in the Latino population of the Exome Aggregation Consortium. Functional studies in patient lymphoblasts carrying the p.Arg324Ter variant demonstrate that variant BCKD enzyme activity is <1% of that of the control enzyme activity. Western blotting experiments showed that the variant resulted in a truncated protein which was not detected in the mitochondria suggesting that the missing amino acids may be necessary for tetramer formation (McConnell et al. 1997; Nellis et al. 2003). Based on the evidence and the potential impact of stop-gained variants, the p.Arg324Ter variant is classified as pathogenic for maple syrup urine disease. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
not provided Pathogenic:3
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Apr 12, 2017 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Maple syrup urine disease type 1B Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 28, 2018 | Variant summary: BCKDHB c.970C>T (p.Arg324X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 6.1e-05 in 245644 control chromosomes (gnomAD). This frequency is not higher than expected for a pathogenic variant in BCKDHB causing Maple Syrup Urine Disease Type 1B (6.1e-05 vs 0.0015), allowing no conclusion about variant significance. c.970C>T has been reported in the literature in multiple individuals affected with Maple Syrup Urine Disease Type 1B (Bashyam_2012, Couce_2015, McConnell_1997, Narayanan_2013, Puckett_2010). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity (McConnell_1997). Three ClinVar submissions from clinical diagnostic laboratories (evaluation after 2014) cites the variant as likely pathogenic/pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Maple syrup urine disease type 1A Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 08, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at